17-04-2025 17:48 via drugs.com

GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM

THURSDAY, April 17, 2025-- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for Alzheimer disease and related dementias (ADRDs) among people with...
Read more »

Pharmaceutical Industry news



Midafternoon Dosing Improves Lung Function in Atopic Asthma
Acute Care for Cannabis Use Increases Risk for Subsequent New Dementia Diagnosis
Recent Years Saw Increase in U.S. Pregnancy-Related Deaths
Guidelines Developed to Improve Newborn Screening for Cystic Fibrosis
Age-Adjusted Ischemic Stroke Mortality Increased Since 2009
MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer
Observation of Predictable Visual Stimuli a Potential Early Indicator for Autism
Gastrointestinal Disease Tied to High Physical, Financial Burden
Digital Technology Linked to Lower Rates of Cognitive Decline in Adults Older Than 50
Study Sheds Light on Role of Risk Factors in Young-Onset Cryptogenic Ischemic Stroke
CT Exams in 2023 Projected to Result in 103,000 Future Cancers
Poor Communication Major Contributor to Patient Safety Incidents
Twins Have Less Fat Accumulation Than Singletons Beginning in Early Pregnancy
Early Pregnancy BP Trajectories Linked to New-Onset HTN Years Later
Desktop versie